• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Namepulse generator, permanent, implantable
Generic Namepulse generator, permanent, implantable
8200 coral sea street ne
ms mv s11
mounds view, MN 55112
PMA NumberP980035
Supplement NumberS013
Date Received09/17/2001
Decision Date03/26/2003
Product Code
NVZ[ Registered Establishments with NVZ ]
Docket Number 03M-0190
Notice Date 05/09/2003
Advisory Committee Cardiovascular
Supplement Typepanel track
Supplement Reason change design/components/specifications/material
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the medtronic at500 dddrp pacing system (model at501) and model 9968 software. The medtronic at500 dddrp pacing system is indicated for the following: 1) rate adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in activity. 2) accepted patient conditions warranting chronic cardiac pacing which include: a)symptomatic paroxysmal or permanent second or third-degree av block. B) symptomatic bilateral bundle branch block. C) symptomatic paroxysmal or transient sinus node dysfunctions with or without associated av conduction disorders. D) bradycardia-tachycardia syndrome to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias. The medtronic at500 system is also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of av synchrony. Dual chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and av synchrony, which include: 1) various degrees of av block to maintain the atrial contribution to cardiac output. 2) vvi intolerance (e. G. , pacemaker syndrome) in the presence of persistent sinus rhythm. Antitachycardia pacing (atp) is indicated for termination of atrial tachyarrhythmias in bradycardia patients with one or more of the above pacing indications. Atrial rhythm management features such as atrial rate stabilization (ars) atrial preference pacing (app), and post mode switch overdrive pacing (pmop) are indicated for the suppression of atrial tachyarrhythmias in bradycardia patients with atrial septal lead placement and one or more of the above pacing indications.
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
Post-Approval StudyShow Report Schedule and Study Progress